428 related articles for article (PubMed ID: 30247903)
1. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
Wang T; Wu X; Guo C; Zhang K; Xu J; Li Z; Jiang S
J Med Chem; 2019 Feb; 62(4):1715-1730. PubMed ID: 30247903
[TBL] [Abstract][Full Text] [Related]
2. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Zhan MM; Hu XQ; Liu XX; Ruan BF; Xu J; Liao C
Drug Discov Today; 2016 Jun; 21(6):1027-36. PubMed ID: 27094104
[TBL] [Abstract][Full Text] [Related]
3. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
4. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.
Lin X; Lu X; Luo G; Xiang H
Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384
[TBL] [Abstract][Full Text] [Related]
5. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Li Y; Li F; Jiang F; Lv X; Zhang R; Lu A; Zhang G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27438833
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
7. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
9. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
10. Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Liu SY; Wu YL
J Hematol Oncol; 2017 Jul; 10(1):136. PubMed ID: 28679395
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.
Wu Q; Jiang L; Li SC; He QJ; Yang B; Cao J
Acta Pharmacol Sin; 2021 Jan; 42(1):1-9. PubMed ID: 32152439
[TBL] [Abstract][Full Text] [Related]
12. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
13. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
14. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
Callea M; Pedica F; Doglioni C
Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
[TBL] [Abstract][Full Text] [Related]
15. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
Front Immunol; 2020; 11():563258. PubMed ID: 33488573
[TBL] [Abstract][Full Text] [Related]
16. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
Li X; Lian Z; Wang S; Xing L; Yu J
Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
19. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
20. [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].
Piętak P; Pietrzyk N; Pawłowska A; Suszczyk D; Bednarek W; Kotarski J; Wertel I
Wiad Lek; 2018; 71(5):1089-1094. PubMed ID: 30176647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]